LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $17.71, Implies 406% Upside

What happened

Analysts’ average 12-month price target for LENZ Therapeutics fell from $17.86 to $17.71, based on estimates from seven analysts. Forecasts ranged from $4 to $45 per share. At the Nov. 3 closing price, the updated target implied about 406% potential upside, while the consensus rating remained Buy.

Confirmed

Global impact / market context

The lower average target points to a modest reduction in analysts’ expectations, while the stated 406% upside is the target’s gap from the Nov. 3 closing price. If investors trade on that perceived gap, buying or selling could change demand for LENZ shares, but targets are forecasts, not guarantees.

Analyst inference

Five of seven analysts covering LENZ rate it Buy, two rate it Hold, and none rate it Sell. Yet the $4–$45 forecast range shows sharply differing views, so the average target may conceal uncertainty about future prospects and the share’s ability to approach that estimate.

Analyst inference

What to watch

1. Watch for later analyst target changes or rating revisions; repeated cuts could weaken investor demand for LENZ shares, while increases could support buying, though neither ensures share gains. Analyst inference
2. Compare future analyst estimates with the current seven-analyst baseline: a changing average or forecast range could shift investors’ expectations and, in turn, buying or selling in LENZ shares. Analyst inference
3. The article reports an average target of $17.71, forecasts from $4 to $45 per share, and a consensus Buy rating among seven analysts; those estimates are not company sales or earnings guidance. Confirmed

Evidence

• Original source link unavailable